Omalizumab is an anti-IgE monoclonal antibody initially approved in 2003 by the FDA for the treatment of moderate-persistent allergic asthma, not controlled with inhaled corticosteroids, being the first immunobiological agente used for type 2 inflammatory diseases.6, 7, 8, 9 Currently, it is indicated also for patients with chronic urticaria, and very recently, for patients with CRSwNP.10 This evidence concerns the gene IGHE and chronic rhinosinusitis with nasal polyps.